“There should be a different therapy for every patient because every patient is different”- William Dempsey (Abbott laboratories)
Treatment of erectile dysfunction , no longer remains an agonizing procedure, earlier ED was treated with injection or through surgery, both of these methods were extremely painful and embarrassing, and worst of all, the success was uncertain.
The emergence of Viagra, Levitra, and Cialis in 1998(FDA approved prescription drugs for erectile dysfunction) revolutionized the entire concept of the treatment of erectile dysfunction. These drugs provided millions of ED patients around the world with the opportunity to renew and re-stabilize their sexual life.
Online Levitra, Cialis and Viagra are all PDE type 5 inhibitors, they helps the blood vessels in the penis to relax, resulting in flow of blood which causes erection. They are all taken orally, and their basic adverse effects are somewhat familiar.
The worth of erectile dysfunction market has grown drastically, it is estimated that by the end of 2006 its income will be $6 billion. 15% of the total male population, nearly 300 million men around the world suffer from impotence and the numbers are not going to decline.
This phenomenal market magnetizes several companies to cash in, its no surprise that numerous companies are rushing in with new and efficient methodology to treat erectile dysfunction.
The information about the additional medical qualities of Apomorphine led to the innovation of Uprima. This sublingual tablet was launched by the Abbott laboratories U.K.
Uprima is a small tablet which dissolves quickly when placed under the - continued below ...
